The abstract is read at the publisher; the summary is JClub's.
More intensive lipid-lowering therapy (rosuvastatin 40 mg plus ezetimibe 10 mg) produced greater coronary plaque regression than intensive therapy in statin-naive stable CAD, with TPV reduction -69.8 mm3 vs -39.0 mm3 at 18 months.
- Why it matters: Prior imaging work showed only modest plaque regression, and it was uncertain whether starting intensive versus more intensive lipid lowering would yield larger, whole-coronary-tree effects in treatment-naive patients.
- What they did: In the FLOWPROMOTE randomized clinical trial (104 statin-naive patients with stable CAD; CTA stenosis >50% and FFR-CT ≤0.80), coronary CTA was repeated at baseline, 9, and 18 months to quantify TPV, NCPV, and CPV.
- The result: At 18 months, NCPV regression was also greater with more intensive therapy (-82.3 mm3 vs -53.5 mm3; both P = .02), regression occurred more often (TPV 90% vs 75%, P = .05; NCPV 98% vs 77%, P = .001), and lower achieved LDL-C was linearly linked to greater TPV and NCPV regression.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.